Mereo BioPharma Group plc 8K

Mereo BioPharma reported Q2 2026 results, announced a Sentynl option/license deal for alvelestat, discussed regulatory next steps for setrusumab with Ultragenyx, and extended its cash runway guidance into late 2027.

On August 11, 2026, Mereo BioPharma Group plc reported its unaudited financial results for the quarter ended June 30, 2026, alongside corporate updates including an option and license agreement with Sentynl Therapeutics for alvelestat, ongoing regulatory discussions with the FDA and MHRA with partner Ultragenyx on a potential path forward for setrusumab in osteogenesis imperfecta after Phase 3 studies missed primary fracture endpoints but showed strong secondary outcomes, and progress by partner āshibio toward a Phase 2 trial of vantictumab in autosomal dominant osteopetrosis type 2, while updating its cash runway guidance to indicate that its $30.1 million in cash and cash equivalents as of June 30, 2026 is expected to fund operations into late 2027, excluding potential option-related payments from Sentynl.

Filing Facts

CIK

1719714

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-343519

Alert Tier

6